Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 2493 • ACR Convergence 2023
Renal Prognosis of Dialysis-dependent Patients at Baseline in ANCA-associated Vasculitis
Maxime Vignac¹, Dorian Nezam², François Grolleau³, Pauline Morel⁴, Dimitri Titeca-Beauport⁵, Stanislas Faguer⁶, alexandre Karras⁷, Justine Solignac⁸, Noémie Jourde-Chiche⁹, Francois Maurier¹⁰, Hamza Sakhi¹, Khalil El Karoui¹, Rafik Mesbah¹¹, Pierre Louis Carron¹², Vincent Audard¹, Didier Ducloux¹³, Romain Paule¹⁴, Jean-François Augusto¹⁵, Julien Aniort¹⁶, Aurélien Tiple¹⁶, Cédric Rafat¹, Xavier Puéchal¹⁷, Pierre Gobert¹⁸, Catherine Hanrotel¹⁹, Stéphane Bally²⁰, Nihal Martis²¹, Cécile-Audrey Durel²², Pascal Godmer²³, Aurélie Hummel²⁴, François Perrin²⁵, Antoine Néel²⁶, Claire De Moreuil²⁷, Tiphaine Goulenok²⁸, Dominique Guerrot²⁹, Aurelie Foucher³⁰, Alban DEROUX¹², Loic Guillevin³¹, Alexis REGENT³², Raphaël Porcher³ and Benjamin Terrier³³, ¹APHP, Paris, France, ²CH du Havre, Havre, France, ³Université Paris Cité, Paris, France, ⁴AURA Paris Plaisance, Paris, France, ⁵CHU Amiens, Amiens, France, ⁶CHU Toulouse, Toulouse, France, ⁷HEGP - APHP, Paris, France, ⁸APHM, Marseille, France, ⁹AP-HM, Marseille, France, ¹⁰Hôpitaux privés de Metz, Vaux / Frankreich, France, ¹¹Boulogne Hospital (CH), Boulogne, France, ¹²CHU de Grenoble, Grenoble, France, ¹³CHU de Besançon, Besançon, France, ¹⁴Hôpital Foch, Paris, France, ¹⁵CHU d'Angers, Angers, France, ¹⁶CHU de Clermont Ferrand, Clermont Ferrand, France, ¹⁷National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ¹⁸Clinique Rhône Durance, Avignon, France, ¹⁹CHU Brest, Brest, France, ²⁰CH Métropole Savoie, Chambery, France, ²¹CHU de Nice, Nice, France, ²²CHU Lyon, Lyon, France, ²³CH Bretagne Atlantique, Vannes, France, ²⁴CHU Necker, Paris, France, ²⁵CH Saint Nazaire, Saint Nazaire, France, ²⁶CHU de Nantes, Nantes, France, ²⁷CHU de Brest, Brest, France, ²⁸Assistance Publique Hopitaux de Paris, Paris, France, ²⁹CHU Rouen, Rouen, France, ³⁰CHU de la Réunion, Saint pierre, France, ³¹University Paris Descartes, Paris, France, ³²CHU Cochin, Université Paris Cité, Paris, France, ³³Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: Renal involvement in ANCA-associated vasculitides (AAV) is an organ- and life-threatening manifestation and therefore an important prognostic factor. However, the identification of predictive factors…
Abstract Number: 0685 • ACR Convergence 2023
Efficacy and Safety of Avacopan in Patients with ANCA-Associated Vasculitis Receiving Rituximab in a Phase 3 Trial
Duvuru Geetha¹, Anisha Dua², Huibin Yue³, Carlo Salvarani⁴, David Jayne⁵ and Peter Merkel⁶, ¹Johns Hopkins University, Baltimore, MD, ²Northwestern University, Chicago, IL, ³Amgen, Inc., Thousand Oaks, CA, ⁴Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: The randomized, double-blind, double-dummy, controlled Phase 3 ADVOCATE trial tested whether avacopan, an oral selective C5a receptor inhibitor approved for the treatment of ANCA-associated…
Abstract Number: 1536 • ACR Convergence 2023
The Impact of COVID-19 Vaccination on ANCA Vasculitis Hospitalisations: A Perspective from Sydney Australia
Dane Turner¹, Grant Luxton¹, Kenneth Yong¹ and Anthony Sammel², ¹South East Sydney Local Health District, Sydney, Australia, ²Prince of Wales Hospital, Randwick, Australia
Background/Purpose: COVID-19 vaccination can trigger a range of inflammatory and auto-immune phenomena, potentially including AAV. There are several international case reports of de novo and…
Abstract Number: 2374 • ACR Convergence 2023
Torque Teno Virus as a Potential Biomarker for Assessment of Immunocompetence in Patients with ANCA-associated Vasculitis
Balazs Odler¹, Regina Riedl¹, Jacinta Lee², Laura Cooney³, Peter Merkel⁴, William St.Clair⁵, Duvuru Geetha⁶, Paul Monach⁷, David Jayne², Rona Smith², Paul A. Lyons², Mark Little⁸, Salem Almaani⁹, Alexander Rosenkranz¹, Ulrich Specks¹⁰, John Stone¹¹ and Andreas Kronbichler¹², ¹Medical University of Graz, Graz, Austria, ²University of Cambridge, Cambridge, United Kingdom, ³Immune Tolerance Network, Seattle, WA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Duke University Medical Center, Durham, NC, ⁶Johns Hopkins University, Baltimore, MD, ⁷VA Boston Healthcare System, Boston, MA, ⁸Trinity College Dublin, Dublin, Ireland, ⁹Ohio State University Medical Center, Columbus, OH, ¹⁰Mayo Clinic, Rochester, MN, ¹¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, ¹²Department of Internal Medicine IV (Nephrology and Hypertension), Innsbruck, Austria
Background/Purpose: ANCA-associated vasculitis (AAV) is a life-threatening disorder characterized by a relapsing-remitting disease course necessitating immunosuppression to control disease activity. Balancing the risks of infection…
Abstract Number: 2494 • ACR Convergence 2023
Complement mRNA Expression in Patients with ANCA-associated Glomerulonephritis
Salem Almaani¹, Arnon Arazi², Huijuan Song³, Pearlly Yan³, Estela Puchulu-Campanella³, Hubao Wang³, Lynn Fussner³, Samir Parikh³ and Brad Rovin³, ¹Ohio State University Medical Center, Columbus, OH, ²Broad Institute of MIT and Harvard, Melrose, MA, ³Ohio State University, Columbus, OH
Background/Purpose: The role of complement in patients with ANCA-associated vasculitis (AAV) has been increasingly appreciated and led to the use of complement system antagonists as…
Abstract Number: 093 • 2023 Pediatric Rheumatology Symposium
Comparison Between Induction with Rituximab and Cyclophosphamide in Treatment of Childhood-Onset ANCA-Associated Vasculitis
Samuel Gagne¹, Kimberly Morishita², Else Bosman³, Vidya Sivaraman⁴, David Cabral⁵, For the PedVas Investigators⁶ and Brett Klamer⁷, ¹Nationwide Children's Hospital, Columbus, OH, ²University of British Columbia, Vancouver, BC, Canada, ³UBC, Vancouver, BC, Canada, ⁴Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ⁵BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁶PedVas, ⁷Biostatistics Resource at Nationwide Children’s Hospital (BRANCH), Nationwide Children’s Hospital, Columbus, OH
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are a group vasculitides with significant morbidity and mortality requiring toxic therapy. Clinical trials in adults…
Abstract Number: L16 • ACR Convergence 2022
Innovative Anti-pneumococcal Vaccine Strategies versus Standard Vaccination Regimen in Patients with ANCA-associated Vasculitides Receiving Rituximab Therapy: A Multicenter Randomized Controlled Trial (PNEUMOVAS)
Benjamin Terrier¹, Laura Richert², Grégory Pugnet³, Olivier Aumaitre⁴, Olivier Moranne⁵, Elisabeth Diot⁶, Alexandre Karras⁷, Fabrice Bonnet⁸, Claire De Moreuil⁹, Eric Hachulla¹⁰, Thomas Le Gallou¹¹, Céline Lebas¹⁰, Francois Maurier¹², Cédric Rafat⁷, Maxime Samson¹³, Jean-Francois Augusto¹⁴, Grégoire Couvrat-Devergne¹⁵, Cécile Janssen¹⁶, Thierry Martin¹⁷, Thomas Quemeneur¹⁸, Pierre-Louis Caron¹⁹, Cécile-Audrey Durel²⁰, Khalil El Karoui⁷, Aurélie Grados²¹, Mathieu Puyade²², Virginie Rieu⁴, Yurdagul Uzunhan²³, Jean-Francois Viallard⁸, Xavier Puéchal⁷, Loic Guillevin⁷, Noémie Huchet⁸, Hendy Abdoul⁷, Carine Bellera⁸, Frédéric Batteux⁷ and Odile Launay⁷, ¹Cochin Hospital, Paris, France, ²EUCLID, Bordeaux, France, ³CHU, Toulouse, France, ⁴CHU, Clermont-Ferrand, France, ⁵CHU, Nimes, France, ⁶CHU, Tours, France, ⁷CHU, Paris, France, ⁸CHU, Bordeaux, France, ⁹CHU, Brest, France, ¹⁰CHU, Lille, France, ¹¹CHU, Rennes, France, ¹²CH, Metz, France, ¹³CHU, Dijon, France, ¹⁴CHU, Angers, France, ¹⁵CH, La Roche sur Yon, France, ¹⁶CH, Annecy, France, ¹⁷CHU, Strasbourg, France, ¹⁸CH, Valenciennes, France, ¹⁹CHU, Grenoble, France, ²⁰CHU, Lyon, France, ²¹CH, Niot, France, ²²CHU, Poitiers, France, ²³CHU, Bobigny, France
Background/Purpose: Patients receiving glucocorticoids plus rituximab (RTX) show an increased risk of infection, especially invasive pneumococcal infections. Vaccine responses to influenza, Streptococcus pneumoniae and SARS-CoV-2…
Abstract Number: 0447 • ACR Convergence 2022
Is Systemic Vasculitis a Risk Factor for Myocardial Infarction? A Retrospective Cohort Study from the National Inpatient Sample
Kavin Raj¹, Marlene Marte Furment², Jyoti Verma³ and Keerthana Jyotheeswara Pillai⁴, ¹University of California Riverside School of Medicine, Riverside, CA, ²SUNY Upstate University Hospital, Syracuse, NY, ³Saint Peter's University Hospital, New Brunswick, NJ, ⁴Kilpauk Medical College, Chennai, India, New Brunswick, NJ
Background/Purpose: Systemic vasculitis is a group of uncommon conditions characterized by inflammation of blood vessels, leading to organ ischemia and necrosis. Although several rheumatological disorders…
Abstract Number: 0700 • ACR Convergence 2022
Accurate Identification of ANCA-Associated Vasculitis Cases from Clinical Notes Using Machine Learning
Liqing Wang¹, John Laurentiev¹, Claire Cook², Eli Miloslavsky², Hyon Choi³, Li Zhou¹ and Zachary Wallace², ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: ANCA-associated vasculitis (AAV) is a rare disease associated with substantial morbidity and mortality.1 To enable outcomes and comparative effectiveness studies using large, phenotypically diverse…
Abstract Number: 1085 • ACR Convergence 2022
Safety of Plasmapheresis as an Adjuvant Therapy in Severe Pediatric Anti-neutrophil Cytoplasmic Antibody Associated Vasculitis: A Single Center Cohort
Sharanya Joginpalli¹, Alvaro Orjuela², Marietta De Guzman³ and Emily Frierson², ¹Baylor College of Medicine- Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Therapeutic plasma exchange (TPE) is used in anti-neutrophil cytoplasmic antibody associated vasculitis (AAV) as adjunct treatment for severe disease. There is paucity of data…
Abstract Number: 0448 • ACR Convergence 2022
All-Cause and Cause-Specific Mortality in ANCA-Associated Vasculitis: A Population-based Study
Anna Wilding¹, Maria Weiner², Jens Rathmann³, Mårten Segelmark¹ and Aladdin Mohammad⁴, ¹Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden, ²Nephrology, Department of Medical and Health Sciences, Linköping, Linköping University, Linköping, Sweden, ³Rheumatology, Department of Clinical Sciences, Lund University, Lund, Skane Lan, Sweden, ⁴Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden
Background/Purpose: Despite improvement in treatment and early diagnosis of ANCA-associated Vasculitis (AAV), mortality remains elevated. Early deaths in AAV patients are often attributed to the…
Abstract Number: 0762 • ACR Convergence 2022
Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders
Christian Ammitzboell¹, marianne Kragh thomsen², Jakob Bøgn Andersen¹, Jens Magnus Berth Jensen³, marie-Louise From Hermansen¹, anders Dahl Johannsen¹, Mads Lamm Larsen¹, Clara Elbæl Mistegaard¹, Susan Mikkelsen³, Fruzsina Szabados³, Signe Risbøl Vils¹, Christian Erikstrup³, Ellen-Margrethe Hauge¹ and Anne Troldborg¹, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Treatment with rituximab (RTX) has presented a challenge during the COVID-19 pandemic, as antibody response after primary vaccination are markedly reduced and often undetectable.The primary…
Abstract Number: 1086 • ACR Convergence 2022
Characteristics and Outcomes of Patients with ANCA Associated Vasculitis Treated with Plasma Exchange: An Analysis of the National Inpatient Sample Database
Vinit Gilvaz¹, Akil Sherif², Sonu Abraham³, Anu Saji² and Anthony Reginato⁴, ¹Brown University, East Providence, RI, ²Saint Vincent Hospital, Worcester, MA, ³Lahey Medical Center, Burlington, MA, ⁴Brown University, Providence, RI
Background/Purpose: Plasma exchange (PLEX) has been used in the management of patients with severe anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) for decades. The most recent…
Abstract Number: 0432 • ACR Convergence 2022
Predictive Factors of Eosinophilic Granulomatosis with Polyangiitis Long-term Evolution: Data from a European Cohort
Matthias Papo¹, Pauline Martinot², Renato A. Sinico³, Vitor Teixeira⁴, Nils Venhoff⁵, Maria-Letizia Urban⁶, Juliane Mahrhold⁷, Francesco Locatelli⁸, Giulia Cassone⁹, Franco Schiavon¹⁰, Benjamin Seeliger¹¹, Thomas Neumann¹², Claus Kroegel¹³, Matthieu Groh¹⁴, Chiara Marvisi¹⁵, Maxima Samson¹⁶, Thomas Barba¹⁷, David Jayne¹⁸, Arianna Troilo¹⁹, Jens Thiel²⁰, Bernhard Hellmich²¹, Sara Monti²², Carlomaurizio Montecucco⁸, Carlo Salvarani²³, Jean-Emmanuel Kahn²⁴, Cecile-Audrey DUREL²⁵, Luc Mouthon²⁶, Loïc Guillevin²⁶, Giacomo Emmi²⁷, Augusto Vaglio²⁸, Raphaël Porcher²⁹ and Benjamin Terrier²⁶, ¹Service De Médecine Interne - Hôpital Cochin, Paris, France, ²Centre of Research in Epidemiology and Statistics, Université de Paris, Paris, Île-de-France, France, Paris, ³Department of Medicine and Surgery, Università degli Studi di Milano – Bicocca, Italy, Milano, Italy, ⁴Hospital de Faro, CHUA, Lisbon, Portugal, ⁵Department of Rheumatology and Clinical Immunology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁶Department of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy, ⁷Department of Internal Medicine, Rheumatology and Immunology, Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, ⁸Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, ⁹Università di Modena e Reggio Emilia, Modena, Italy, ¹⁰Operative Unit of Rheumatology, Department of Medicine DIMED, University of Padova, Padova, Italy, ¹¹Department of Respiratory Medicine, Hannover Medical School, Wermsdorf, Germany, ¹²Kantonsspital St. Gallen, St. Gallen, Switzerland, ¹³Department of Pneumology and Allergology, Clinic of Internal Medicine I, Jena University Hospital, Jena, Germany, ¹⁴Service de Médecine Interne, Centre de Référence des Syndromes Hyperéosinophiliques-CEREO, Hôpital Foch, Université Versailles–Saint-Quentin-en-Yvelines, Suresnes, France, ¹⁵Università di Modena e Reggio Emilia and National Institute of Arthritis & Musculoskeletal & Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁶Dijon University Hospital, Dijon, France, ¹⁷Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France, ¹⁸University of Cambridge, Cambridge, United Kingdom, ¹⁹Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ²⁰University Hospital Freiburg, Freiburg, Germany, ²¹Klinik für Innere Medizin, Rheumatologie & Immunologie, Medius Kliniken, Universität Tübingen, Plochingen, Germany, ²²Rheumatology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, ²³Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Reggio Emilia, Italy, ²⁴Service de médecine interne - Hôpital Ambroise Paré, AP-HP, Boulogne-Billancourt, France, ²⁵CHU Lyon, Lyon, France, ²⁶National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²⁷Azienda Ospedaliero Universitaria Careggi, Firenze, Italy, ²⁸Azienda Ospedaliero Universitaria Meyer, Parna, Italy, ²⁹Université Paris Cité, Hôtel-Dieu, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small vessel necrotizing vasculitis characterized by blood and tissue eosinophilia and asthma. Glucocorticoids (GCs) frequently control the…
Abstract Number: 0449 • ACR Convergence 2022
Higher Disease Acuity at Presentation and Increased Lower Respiratory Involvement in Hispanic and Black Patients with ANCA-Associated Vasculitis
Mark Riley¹, Wenlu Xiong¹ and Najia Shakoor², ¹Rush University Medical Center, Chicago, IL, ²Rush University, Hinsdale, IL
Background/Purpose: ANCA-associated vasculitis (AAV) is a systemic small-vessel vasculitis comprising granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA), and renal-limited vasculitis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].